Efficacy and Safety of Intracavernous Administration of Platelet-Rich Plasma in the Treatment of Erectile Dysfunction in Kazakh Population: Results of a Six-Month Follow-Up

Rinat Nugumanov 1, Rustam Omarbayev 2 * , Yerbol Iskakov 2, Alexey Suchshenko 3, Yerkebulan Yermaganbetov 2, Damir Akhmetkaliyev 2, Manarbek Askarov 4, Abai Baigenzhin 5
More Detail
1 Medi-Art Clinic, Astana, Kazakhstan
2 Department of Urology, JSC “National Scientific Medical Center”, Astana, Kazakhstan
3 Department of urology and andrology, JSE «Astana Medical University», Astana, Kazakhstan
4 Institute of Fundamental and Applied Medicine, JSC “National Scientific Medical Center”, Astana, Kazakhstan
5 Chairman of the Board, JSC "National Scientific Medical Center", Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 5, pp. 58-65. https://doi.org/10.23950/jcmk/17249
OPEN ACCESS 164 Views 50 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, R.N., R.O.; methodology, Y.I., A.S. and Y.Y.; validation, D.A., A.M. and A.B.; formal analysis, R.N.; investigation, Y.I., A.S. and Y.Y.; resources, R.N.; data curation, R.N.; writing – original draft preparation, D.A., A.M. and A.B.; writing – review and editing, R.O., A.S.; visualization, Y.I..;  supervision, Y.Y.; project administration, A.B.; funding acquisition, R.N. All authors have read and agreed to the published version of the manuscript.

ABSTRACT

Эректильная дисфункция (ЭД) является распространенной проблемой, которая может поражать мужчин всех возрастов и оказывать влияние на психическое и стабильное здоровье и общее качество жизни. В Казахстане из 1550 обследованных мужчин (в возрасте от 21 до 79 лет) у 784 была диагностирована ЭД (52,3%). В последние годы, с развитием генных и регенеративных технологий, появилась новая перспективная стратегия лечения метода ЭД: трансплантация мезенхимических стволовых клеток, полученных из костного мозга, и мезенхимических стромальных клеток, полученных из жировой ткани.
Аутологичная богатая тромбоцитами плазма (PRP) содержит стабильность тромбоцитов в три-семь раз последовательной выше нормы и богата факторами роста, хемокинами и ангиогенными факторами. Поэтому было проведено проспективное исследование на казахской практике, чтобы изучить безопасность и эффективность интракавернозных инъекций PRP у пациентов со средней и тяжелой ЭД.
Использование терапии PRP для лечения средней степени тяжести и ЭД безопасно, но малоэффективно. Активация хлорида PRP не дала конкретных результатов. Следовательно, более высокие дозировки могут иметь значение с лучшими краткосрочными последствиями. Методика PRP-терапии требует дальнейшего тщательного изучения и разработки методик применения PRP в клинической практике, особенно для лечения тяжёлых и среднетяжёлых форм эректильной дисфункции. Для окончательной оценки эффективности PRP-терапии в улучшении эректильной функции необходимы дополнительные проспективные рандомизированные плацебо-контролируемые исследования.
Keywords: platelet-rich plasma, erectile dysfunction, intracavernous injections.

CITATION

Nugumanov R, Omarbayev R, Iskakov Y, Suchshenko A, Yermaganbetov Y, Akhmetkaliyev D, et al. Efficacy and Safety of Intracavernous Administration of Platelet-Rich Plasma in the Treatment of Erectile Dysfunction in Kazakh Population: Results of a Six-Month Follow-Up. J CLIN MED KAZ. 2025;22(5):58-65. https://doi.org/10.23950/jcmk/17249

REFERENCES

  • Hatzimouratidis (Chair) K, Giuliano F, Moncada I, Muneer A, Salonia A (Vice-chair), Verze P. Guideline Associates: Parnham A, Serefoglu EC. Male sexual dysfunction. EAU Guidelines Office, Arnhem, The Netherlands. 2018. ISBN 978-90-79754-91-5. http://uroweb.org/guidelines/compilations-of-all-guidelines/
  • Eid JF, Nehra A, Andersson KE, Heaton J, Lewis RW, Morales A, Moreland RB, Mulcahy JJ, Porst H, Pryor JL, Sharlip ID, Wagner G, Wyllie M. First international conference on the management of erectile dysfunction. Overview consensus statement. International Journal of Impotence Research. 2000;12 Suppl 4:S2-5. https://doi.org/10.1038/sj.ijir.3900600.
  • Keshtkar V, Zarmehrparirouy M, Izadi MA, Sharifi MH. Predictive factors of sexual dysfunction and quality of life among type 2 diabetes outpatients in southern Iran: a cross-sectional survey. BMJ Open. 2025;15(3):e082327. https://doi.org/10.1136/bmjopen-2023-082327.
  • Zhang J, Xin S, Mao J, Liu X, Wang T, Liu J, Song X, Song W. The role of programmed cell death in diabetes mellitus-induced erectile dysfunction: from mechanisms to targeted therapy. Reprod Biol Endocrinol. 2025;23(1):32. https://doi.org/10.1186/s12958-025-01368-1.
  • Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. The American Journal of Medicine 2007;120(2):151-157. https://doi.org/10.1016/j.amjmed.2006.06.010.
  • Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy. 2001;21(6):676-83. https://doi.org/10.1592/phco.21.7.676.34571.
  • Khamzin A, Frolov R. [Andrological aspects of men's health in Kazakhstan]. Georgian Med News. 2015;(242):7-12. Russian. PMID: 26042441.
  • Sikhymbaev M, Ospanova D, Grzhibovsky A, Akkaliyev M, Kurmanbekov T, Tanabayeva S, Saliev T, Altynbekov S, Fakhradiyev I. Evaluation of the sexual function of men in Kazakhstan during 2021-2022: A cross-sectional study. Health science reports. 2023; 28;6(3):e1142. https://doi.org/10.1002/hsr2.1142.
  • Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-79. https://doi.org/10.2337/diacare.26.5.1553.
  • Guay AT. Sexual dysfunction in the diabetic patient. International journal of impotence research. 2001;13 Suppl 5:S47-50. https://doi.org/10.1038/sj.ijir.3900779.
  • Schiel R, Müller UA. Prevalence of sexual disorders in a selection-free diabetic population (JEVIN). Diabetes research and clinical practice. 1999;44(2):115-21. https://doi.org/10.1016/S0168-8227(99)00012-1.
  • Brunner GA, Pieber TR, Schattenberg S, Ressi G, Wieselmann G, Altziebler S, Krejs GJ. Erektile Dysfunktion bei Patienten mit Diabetes mellitus Typ I [Erectile dysfunction in patients with type I diabetes mellitus]. Wiener medizinische Wochenschrift. 1995;145(21):584-6. German.
  • Kogan M.I., Kalinichenko S.Y., Rozhivanov R.V. Sexual dysfunction in men with diabetes mellitus. Manual for doctors. Edited by M.I. Kogan. Moscow, 2005; p. 218.
  • Zhang J, Xin S, Mao J, Liu X, Wang T, Liu J, Song X, Song W. The role of programmed cell death in diabetes mellitus-induced erectile dysfunction: from mechanisms to targeted therapy. Reproductive biology and endocrinology: RB&E. 2025;23(1):32. https://doi.org/10.1186/s12958-025-01368-1.
  • Kaltsas A, Giannakodimos I, Markou E, Adamos K, Stavropoulos M, Kratiras Z, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M. The Role of Gut Microbiota Dysbiosis in Erectile Dysfunction: From Pathophysiology to Treatment Strategies. Microorganisms. 2025;13(2):250. https://doi.org/10.3390/microorganisms13020250.
  • Wang G, Ni C. Association of erectile dysfunction and peripheral arterial disease in NHANES 2001-2004: a cross-sectional study. Frontiers in endocrinology. 2024; 6;15:1439609. https://doi.org/10.3389/fendo.2024.1439609.
  • El Assar M, García-Gómez B, La Fuente JM, Alonso-Isa M, Martínez-Salamanca JI, Fernández A, Sosa P, Romero-Otero J, Rodríguez-Mañas L, Angulo J. Targeting TRPC-5 Channel Inhibition to Improve Penile Vascular Function in Erectile Dysfunction. International journal of molecular sciences. 2025;26(4):1431. https://doi.org/10.3390/ijms26041431
  • Dhir RR, Lin HC, Canfield SE, Wang R. Combination therapy for erectile dysfunction: an update review. Asian journal of andrology. 2011;13(3):382-90. https://doi.org/10.1038/aja.2011.2.
  • Sun L, Peng FL, Yu ZL, Liu CL, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. International journal of urology: official journal of the Japanese Urological Association. 2014;21(12):1263-7. https://doi.org/10.1111/iju.12564.
  • Torremadé J, Presa M, Gorría Ó, de Burgos R, Oyagüez I, Lledó E. Systematic review of the implantation of penile prosthesis in major ambulatory surgery. Actas urologicas españolas. 2023;47(6):341-350. https://doi.org/10.1016/j.acuroe.2022.08.019.
  • Sun C, Lin H, Yu W, Li X, Chen Y, Qiu X, Wang R, Dai Y. Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats. International journal of andrology. 2012;35(4):601-7. https://doi.org/10.1111/j.1365-2605.2012.01250.x.
  • Fang JF, Jia CC, Zheng ZH, Ye XL, Wei B, Huang LJ, Wei HB. Periprostatic implantation of neural differentiated mesenchymal stem cells restores cavernous nerve injury-mediated erectile dysfunction. American journal of translational research. 2016;8(6):2549-61. PMCID: PMC4931150
  • Zhang H, Albersen M, Jin X, Lin G. Stem cells: Novel players in the treatment of erectile dysfunction. Asian journal of andrology, 2011;14:145–155. https://doi.org/10.1038/aja.2011.79
  • Abdel Aziz MT, El-Haggar S, Mostafa T, Atta H, Fouad H, Mahfouz S, Rashed L, Sabry D, Senbel A, Ali GA. Effect of mesenchymal stem cell penile transplantation on erectile signaling of aged rats. Andrologia. 2010;42(3):187-92. https://doi.org/10.1111/j.1439-0272.2009.00977.x
  • Ying C, Yang M, Zheng X, Hu W, Wang X. Effects of intracavernous injection of adipose-derived stem cells on cavernous nerve regeneration in a rat model. Cellular and molecular neurobiology. 2013;33(2):233-40. https://doi.org/10.1007/s10571-012-9890-7.
  • Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C, Taylor BK, Murthy SN, Champion HC, Hellstrom WJ, Kadowitz PJ. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American journal of physiology. Heart and circulatory physiology. 2007;292(3):H1278-90. https://doi.org/10.1152/ajpheart.00685.2006.
  • Zhang X, Yang M, Chen X, Zhang M, Peng Y, Lu M. Melatonin-pretreated mesenchymal stem cell-derived exosomes alleviate cavernous fibrosis in a rat model of nerve injury-induced erectile dysfunction via miR-145-5p/TGF-β/Smad axis. Stem cell research & therapy. 2025;16(1):96. https://doi.org/10.1186/s13287-025-04173-0.
  • Liu G, Sun X, Bian J, Wu R, Guan X, Ouyang B, Huang Y, Xiao H, Luo D, Atala A, Zhang Y, Deng C. Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS One. 201;8(8):e72790. https://doi.org/10.1371/journal.pone.0072790.
  • André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Nedellec G, Attal M, Fermé C, Gisselbrecht C. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood. 1998;92(6):1933-40.
  • Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality? Sexual Medicine Reviews. 2020;8(1):106-113. https://doi.org/10.1016/j.sxmr.2019.02.002
  • Liu MC, Chang ML, Wang YC, Chen WH, Wu CC, Yeh SD. Revisiting the Regenerative Therapeutic Advances Towards Erectile Dysfunction. Cells. 2020;9(5):1250. https://doi.org/10.3390/cells9051250
  • Smith RG, Gassmann CJ, Campbell MS. Platelet rich plasma: Properties and clinical application. The Journal of Lancaster General Hospital, 2007; 2:73–78. PMCID: PMC4931150
  • Matz E.L., Perlman A.M., Terletskiy R. Safety and feasibility of platelet-rich fibrin matrix injections for the treatment of common urological diseases. Investig Clin Urol, 2018; 59:61. https://doi.org/10.4111/icu.2018.59.1.61
  • Zaghloul AS, Mahmoud ElNashar AER, GamalEl Din SF, Zaki Said S, Saad HM, Refaat Eldebs H, Abdel Latif Osman I. Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet-rich plasma in patients with erectile dysfunction: A prospective pilot study. Andrologia. 2021;53(9):e14162. https://doi.org/10.1111/and.14162.
  • Zaghloul AS, El-Nashaar AM, Said SZ, Osman IA, Mostafa T. Assessment of the intracavernosal injection platelet-rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non-responding to on-demand oral PDE5 inhibitors. Andrologia. 2022;54(6):e14421. https://doi.org/10.1111/and.14421
  • Asmundo MG, Durukan E, von Rohden E, Thy SA, Jensen CFS, Fode M. Platelet-rich plasma therapy in erectile dysfunction and Peyronie's disease: a systematic review of the literature. World journal of urology. 2024;42(1):359. https://doi.org/10.1007/s00345-024-05065-3
  • Corona G, Rastrelli G, Burri A, Serra E, Gianfrilli D, Mannucci E, Jannini EA, Maggi M. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. Andrology. 2016;4(6):1002-1009. https://doi.org/10.1111/andr.12255.
  • Stridh A, Pontén M, Arver S, Kirsch I, Abé C, Jensen KB. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(3):e201423. https://doi.org/10.1001/jamanetworkopen.2020.1423.
  • Shahinyan RH, Amighi A, Carey AN, Yoffe DA, Hodge DC, Pollard ME, Nork JJ, Mills JN, Eleswarapu SV. Direct-To-Consumer Internet Prescription Platforms Overlook Crucial Pathology Found During Traditional Office Evaluation of Young Men With Erectile Dysfunction. Urology. 2020;143:165-172. https://doi.org/10.1016/j.urology.2020.03.067.
  • Shahinyan GK, Weinberger JM, Shahinyan RH, Yang SC, Mills JN, Eleswarapu SV. Analysis of Direct-to-Consumer Marketing of Platelet-Rich Plasma for Erectile Dysfunction in the US. JAMA Network Open. 2022;5(5):e2214187. https://doi.org/10.1001/jamanetworkopen.2022.45075.
  • Liu JL, Chu KY, Gabrielson AT, Wang R, Trost L, Broderick G, Davies K, Brock G, Mulhall J, Ramasamy R, Bivalacqua TJ. Restorative Therapies for Erectile Dysfunction: Position Statement From the Sexual Medicine Society of North America (SMSNA). Sexual medicine. 2021;9(3):100343. https://doi.org/10.1016/j.esxm.2021.100343.
  • Masterson TA, Molina M, Ledesma B, Zucker I, Saltzman R, Ibrahim E, Han S, Reis I, Ramasamy R. Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial. Reply. The Journal of urology. 2023;210(5):734-735. https://doi.org/10.1097/JU.0000000000003685.
  • Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. Journal of cutaneous and aesthetic surgery. 2014;7(4):189-97. https://doi.org/10.4103/0974-2077.150734.
  • Sadeghi-Ataabadi M, Mostafavi-Pour Z, Vojdani Z, Sani M, Latifi M, Talaei-Khozani T. Fabrication and characterization of platelet-rich plasma scaffolds for tissue engineering applications. Materials science and engineering. C, Materials for biological applications. 2017;71:372-380. https://doi.org/10.1016/j.msec.2016.10.001.
  • Anitua E, Muruzabal F, de la Fuente M, Merayo J, Durán J, Orive G. Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases. Current eye research. 2016;41(7):875-82. https://doi.org/10.3109/02713683.2015.1104362.
  • Patel AN, Selzman CH, Kumpati GS, McKellar SH, Bull DA. Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients. Journal of cardiothoracic surgery. 2016;11(1):62. https://doi.org/10.1186/s13019-016-0452-9.
  • Shaher H, Fathi A, Elbashir S, Abdelbaki SA, Soliman T. Is Platelet Rich Plasma Safe and Effective in Treatment of Erectile Dysfunction? Randomized Controlled Study. Urology. 2023;175:114-119. https://doi.org/10.1016/j.urology.2023.01.028.
  • Anastasiadis E, Ahmed R, Khoja AK, Yap T. Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence. Frontiers in reproductive health. 2022;4:944765. https://doi.org/10.3389/frph.2022.944765.